Invion

Invion OpEx/Revenue

The Operating Expenses to Revenue Ratio of Invion (IVX.AX) as of Oct 12, 2026 is 934.40 %. In the previous year, Operating Expenses to Revenue Ratio was 108.89 % — a change of 758.13% (higher).

OpEx/Revenue

934.40 %

YoY

758.13%

Last updated:

Operating Expenses to Revenue Ratio of Invion is 2026 934.40 % . Operating Expenses to Revenue Ratio of Invion was 2025 108.89 % . It decreases by 758.13% higher compared to the previous year.

The Invion OpEx/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OpEx/Revenue
Date
OpEx/Revenue
Jan 1, 2018
153.58 AUD
Jan 1, 2019
93.81 AUD
Jan 1, 2020
66.47 AUD
Jan 1, 2021
101.47 AUD
Jan 1, 2022
104.50 AUD
Jan 1, 2023
96.11 AUD
Jan 1, 2024
108.89 AUD
Jan 1, 2026
934.40 AUD
The Invion OpEx/Revenue history
YEAROpEx/RevenueYoY
934.40 %+758.13%
108.89 %+13.29%
96.11 %-8.03%
104.50 %+2.99%
101.47 %+52.66%
66.47 %-29.15%
93.81 %-38.92%
153.58 %-93.88%
2,511.04 %-60.74%
6,396.70 %+167.67%
2,389.79 %—
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Operating Expenses to Revenue Ratio of Invion is 934.40 % in 2026.

Operating Expenses to Revenue Ratio of Invion changed from 108.89 % to 934.40 %, representing a 758.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio Invion since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

Margins — Invion

All Key Metrics — Invion